Recent insights from genetic studies suggest that TG-rich lipoproteins causally influence atherosclerosis and its associated complications. [11] [12] [13] Furthermore, lipolysis of TG-rich lipoproteins yields TG-depleted, cholesterol-rich remnant lipoproteins that contain ≤20× more cholesterol per particle than LDLC, © 2016 American Heart Association, Inc. Objectives-Non-high-density lipoprotein cholesterol (non-HDLC) levels reflect the full burden of cholesterol transported in atherogenic lipoproteins. Genetic studies suggest a causal association between elevated triglycerides (TGs)-rich lipoproteins and atherosclerosis. We evaluated associations between achieved non-HDLC and TG levels on changes in coronary atheroma volume. Approach and Results-Data were analyzed from 9 clinical trials involving 4957 patients with coronary disease undergoing serial intravascular ultrasonography to assess changes in percent atheroma volume (∆PAV) and were evaluated against on-treatment non-HDLC and TG levels. The effects of lower (<100 mg/dL) versus higher (≥100 mg/dL) achieved non-HDLC levels and lower (<200 mg/dL) versus higher (≥200 mg/dL) achieved TG levels were evaluated in populations with variable on-treatment low-density lipoprotein cholesterol (LDLC) </≥70 mg/dL and C-reactive protein </≥2 mg/L and in patients with or without diabetes mellitus. On-treatment non-HDLC levels linearly associated with ∆PAV. Overt PAV progression (∆PAV>0) was associated with achieved TG levels >200 mg/dL, respectively. Lower on-treatment non-HDLC and TG levels associated with significant PAV regression compared with higher non-HDLC and TG levels across all levels of LDLC and C-reactive protein and irrespective of diabetic status (P<0.001 across all comparisons). ∆PAV were more strongly influenced by changes in non-HDLC (β=0.62; P<0.001) compared with changes in LDLC (β=0.51; P<0.001). Kaplan-Meier sensitivity analyses demonstrated significantly greater major adverse cardiovascular event rates in those with higher versus lower non-HDLC and TG levels, with an earlier separation of the non-HDLC compared with the LDLC curve. Conclusions-Achieved non-HDLC levels seem more closely associated with coronary atheroma progression than LDLC.
S tatin-mediated low-density lipoprotein cholesterol (LDLC) lowering significantly reduces both primary and secondary cardiovascular events in randomized controlled trials. 1 These data underscore the paradigm of statin-mediated LDLC lowering as the primary means of reducing cardiovascular event rates. Yet a considerable portion of statin-treated individuals continue to experience subsequent cardiovascular events, indicative of their residual cardiovascular risk. 2 
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Non-high-density lipoprotein cholesterol (non-HDLC) encompasses all of the atherogenic apolipoprotein B (apoB)-containing lipoproteins (LDLC, very low-density lipoprotein cholesterol, intermediate-density lipoprotein cholesterol, lipoprotein (a), chylomicrons, and their triglyceride (TG)-rich remnants). Population studies have outlined non-HDLC to better predict cardiovascular risk compared with LDLC alone, [3] [4] [5] even among statin-treated individuals. 6 Although the latest US cholesterol treatment guidelines have shifted emphasis away from targeting specific LDLC levels in patients with atherosclerotic cardiovascular disease, 7 non-HDLC continues to receive much less attention, remaining a secondary treatment goal within current European guidelines. 8 However, recently, both the International Atherosclerosis Society and National Lipid Association have flagged non-HDLC as the major form of atherogenic cholesterol and a primary therapeutic target. 9, 10 more avidly crossing the endothelial barrier.
14 Accordingly, the relationship between achieved non-HDLC and TG levels upon coronary atheroma progression rates has yet to be defined.
Coronary intravascular ultrasound is a sensitive imaging tool for measuring coronary atheroma volume and continues to play an important role for evaluating the antiatherosclerotic effects of novel therapies on serial measures of coronary disease progression. 15, 16 Post hoc analyses of serial intravascular ultrasound trials demonstrated significant associations between measures of disease progression and incident cardiovascular events. [17] [18] [19] The present analysis aimed to define the relationship between achieved non-HDLC and TG levels with rates of coronary atheroma progression. The effects of higher versus lower non-HDLC and TG levels on plaque progression rates were specifically explored within patients stratified according to varying degrees of residual metabolic risk (defined according to achieved LDLC, C-reactive protein [CRP] , and diabetes mellitus status).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Table 1 describes baseline demographics, clinical characteristics, and medication use of the pooled study population (n=4957). Mean age was 57.9±9 years, 28.1% were female, 29% had diabetes mellitus, and the mean body mass index was 30.8±5.8 kg/m 2 . Notably, 74% received prior statin therapy, and concomitant (on-trial) rates of statins, aspirin, β-blockers, and angiotensin-converting enzyme inhibitor/ angiotensin-receptor blocker use were 96%, 94%, 76%, and 68%, respectively. Table 2 describes baseline, follow-up, and changes in plaque and laboratory biochemical measurements. In the overall population, the median change in LDLC was −14.4%; non-HDLC, −13.6%; HDLC, +13.0%; TG, −7.2%; and CRP, −25.0%. These biochemical changes associated with no net change in percent atheroma volume (PAV) within the overall study population (median [95% confidence interval (CI)] change in PAV =+0.01 [−0.08, 0.11]; P=0.76). Figure 1 illustrates the relationship between the full range of average on-treatment non-HDLC and TG levels against changes in coronary PAV. Individual patient-level data are represented as LOWESS (locally weighted scatter plot smooth) plots. Although achieved non-HDL levels and coronary atheroma progression rates seem linearly related, the rate of disease progression increases as TG levels rise >110 mg/dL and start to associate with actual disease progression (∆PAV>0) beyond TG levels of 200 mg/dL. Figure 2 illustrates the effect of lower (<100 mg/dL) and higher (≥100 mg/dL) on-treatment non-HDLC levels on coronary atheroma progression rates across specific populations at varying metabolic risk. These data demonstrate that lower compared with higher non-HDLC levels associated significantly with greater PAV regression, irrespective of achieved LDLC levels, CRP levels, or diabetic status (P<0.001 for all comparisons). Point estimates of changes in PAV for all patient groups are provided in Table I in the online-only Data Supplement. Figure 3 illustrates the effect of lower (<200 mg/dL) and higher (≥200 mg/dL) on-treatment TG levels on coronary atheroma progression rates across specific populations at varying metabolic risk. Similar to the results demonstrated in Figure 2 , lower compared with higher TG levels associated significantly with greater PAV regression, irrespective of achieved LDLC levels, CRP levels, or diabetic status (P<0.001 for all comparisons). Point estimates of changes in PAV for all patient groups are provided in Table II in the online-only Data Supplement.
Results

Clinical Characteristics of the Study Population
Plaque and Laboratory Biochemical Measurements
Relationships Between Non-HDLC, TG, and Coronary Atheroma Progression
Effects of Higher Versus Lower Non-HDLC and TG on Coronary Atheroma Progression
Comparative Influence of LDLC and Non-HDLC on Coronary Atheroma Progression/Regression
Given that LDLC and non-HDLC are intrinsically related (colinear), the relative strength of association of these Table 4 
Relationship Between Non-HDLC, TG, LDLC, and Major Adverse Cardiovascular Event
Sensitivity analyses were performed comparing the impact of achieved non-HDLC, TG, and LDLC levels on major adverse cardiovascular event (MACE; Figures IV and V in the online-only Data Supplement). Figure IVA in the online-only Data Supplement illustrates Kaplan-Meier curves assessing MACE across patients stratified according to on-treatment non-HDLC levels < versus ≥ median. At 24 months, cumulative incidence of first MACE was significantly greater in those with achieved non-HDLC levels ≥ median level compared with non-HDLC < median value (22.8% versus 14.6%; log-rank P<0.001). Figure IVB in the online-only Data Supplement illustrates the comparative Kaplan-Meier curves of patients stratified according to on-treatment LDLC levels < versus ≥ median. At 24 months, cumulative incidence of first MACE was significantly greater in those with achieved LDLC ≥ versus <median value (22.0% versus 15.5%; log-rank P<0.001). Closer inspection of Figures IVA and IVB in the online-only Data Supplement illustrates the slightly earlier and more consistent curve separation in the non-HDLC-stratified population compared with the LDLCstratified population.
Figure VA in the online-only Data Supplement illustrates Kaplan-Meier curves assessing MACE across patients stratified according to on-treatment TG levels < versus ≥ median, illustrating that cumulative incidence of first MACE at 24 months was significantly greater in those with ≥ median TG levels (21.2% versus 15.9%; log-rank P<0.001). Figure VB in the online-only Data Supplement stratifies the population according to on-treatment TG levels < versus ≥200 mg/dL, illustrating significantly higher cumulative incidence of first MACE within patients with TG ≥200 mg/dL compared with lower TG levels (23.7% versus 17.5%; log-rank P<0.001). 
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Discussion
The present analysis is the first to demonstrate that coronary disease progression seems more tightly linked with changes in non-HDLC compared with LDLC and that on-treatment TG levels associate with coronary atheroma progression (and, thus, cardiovascular risk), especially when these levels exceed 200 mg/dL. Moreover, achieved non-HDLC and TG levels significantly modulated plaque progression-regression rates across broad categories of residual cardiovascular risk, including those with achieved LDLC levels <70 mg/dL. These findings provide mechanistic support for the possible roles of non-HDLC and TG to more definitively emerge as future therapeutic targets, especially in statin-treated patients requiring secondary prevention. Although the benefits of LDLC lowering are well established, 1, 20 many patients continue to experience cardiovascular events, despite achieving low LDLC levels. 2 The global obesity, diabetes mellitus, and metabolic syndrome epidemic is increasing the prevalence of atherogenic TG-rich remnant lipoproteins, 21 which are more effectively accounted for by measuring the non-HDLC, but not the LDLC fraction. The present analysis outlines a consistent antiatherosclerotic effect of lower achieved non-HDLC levels, even within populations whose residual risk is already considered to be low (patients with LDLC <70 mg/dL and CRP <2 mg/L). Although we uncovered a relatively stronger correlation between coronary plaque progression-regression and non-HDLC levels compared with LDLC levels, Kaplan-Meier sensitivity analyses (see online-only Data Supplement) also revealed higher non-HDLC levels to associate with an earlier, slightly more dominant effect on MACE compared with corresponding LDLC stratification. Our observations are, therefore, consistent with the known capacity of non-HDLC to better predict MACE compared with LDLC in epidemiological studies, [3] [4] [5] 22 supporting the potential role of non-HDL as possible primary therapeutic targets in future prospective clinical trials. 23 Although the exact role of TGs in mediating atherosclerosis continues to be debated, 24 genetic studies strongly suggest that elevated TG-rich lipoprotein concentrations are a causal risk factor for atherosclerotic disease. 25 Elevated TG concentrations reliably indicate raised levels of remnant cholesterol (the cholesterol content of TG-rich lipoproteins). However, clinical trials testing the efficacy of TG-lowering strategies have largely been negative. 26, 27 This may be in part because of baseline TG levels in these trials being potentially too low to demonstrate an anti-atherosclerotic effect, with the median baseline TG levels in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) and ORIGIN (Outcome Reduction With an Initial Glargine Intervention) trials being 162 and 142 mg/dL, respectively. The current analysis suggests that the rate coronary disease progression (and, thus, atherosclerotic risk) seems well established when TG levels exceed 200 mg/dL. Collectively, these data support the notion that patients with TG levels >200 mg/dL are more likely to derive clinical benefit from a TG-lowering intervention. This hypothesis is currently being tested in 2 large-scale clinical trials (NCT02104817 and NCT01492361).
The comparative multivariable analyses in Tables 3 and 4 demonstrate the significant dual effect of both higher LDLC and TG levels independently associating with disease progression. However, the non-HDLC-adjusted analysis outlined a more dominant effect of non-HDLC levels on plaque progression. Cholesterol-rich remnants found within the non-HDLC fraction more avidly cross the endothelial barrier. 14 These processes promote foam cell accumulation, lipid-core expansion, and plaque progression. Histological analysis of severely stenotic carotid plaques demonstrated a direct association between macrophage content and TG-rich lipoprotein remnants synonymous with the non-HDLC fraction.
28 Figure 1 . LOWESS (locally weighted scatter plot smooth) regression was used to evaluate the overall associations between on-treatment low-density lipoprotein cholesterol (LDL-C; A), nonhigh-density lipoprotein cholesterol (non-HDLC; B), and triglyceride (TG) levels (C) against changes in percent atheroma volume (PAV).
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To complement histological findings, human plaque imaging studies have been pivotal in elucidating mechanisms promoting atheroma progression, stabilization, and regression.
However, the present analysis represents the first description of the direct impact of on-treatment non-HDLC and TG levels on serial changes in coronary plaque volume. Our findings also have possible implications for clinical practice. There is a notable discordance between non-HDLC and LDLC levels in the US population. 29, 30 A sizeable proportion of individuals with LDLC levels <70 mg/dL harbor non-HDLC levels ≥100 mg/dL, effectively reclassifying their cardiovascular risk. Previous guidelines set non-HDLC goals 30 mg/dL higher than respective LDLC goals and relegated non-HDLC as a secondary treatment target only in patients Figure 3 . Interactions of dichotomous categories of on-treatment triglyceride (TG) levels (<200 vs ≥200 mg/dL) and various metabolic risk binary variables were assessed for their effects on changes in coronary percent atheroma volume (PAV). Comparisons with predicted least-squares means of PAV were made between TG <200 and ≥200 mg/dL in each of the metabolic risk binary subcategories, and all analyses were adjusted for baseline PAV levels. A, On-treatment low-density lipoprotein cholesterol (LDLC) <70 vs ≥70 mg/dL. Mean 
with TG levels ≥200 mg/dL. 31 Yet the present analysis suggests an antiatherosclerotic benefit of lower non-HDLC levels even in patients with LDLC levels <70 mg/dL. Furthermore, the latest US cholesterol treatment guidelines no longer advocate LDLC goals and recommend empirical high-intensity statin therapies in high-risk patients or in those with established atherosclerotic disease. 7 In the absence of current LDLC targets, our data provides mechanistic support for adopting non-HDLC treatment goals, particularly in high-risk patients receiving statins. This strategy has been postulated to prevent 300 000 more MACE in the US over a 10-year period compared with an LDLC-only treatment strategy. 32 Thus, further consideration could be given for setting non-HDLC goals lower than previously recommended. 33 This analysis has limitations. These findings are applicable to patients with established coronary artery disease with an indication for coronary angiography and cannot be extrapolated to patients without clinically evident atherosclerotic disease. Despite the known association between changes in intravascular ultrasound-derived coronary atheroma volume and MACE, [17] [18] [19] none of the reported serial intravascular ultrasound trials in the current analysis were powered to detect differences in MACE. However, our serial plaque imaging data are extremely consistent with more contemporary epidemiological, genetic, and mechanistic observations that collectively outline the dominant role of non-HDLC and TG in mediating atherosclerotic risk. Although our multivariable models were appropriately adjusted for clinical trial, time-dependent variations of these trials (18-24 months) , and a range of baseline and on-treatment covariates, we cannot exclude unmeasured confounding variables that could have biased our results. Even though information on baseline and concomitant medications and general cardiovascular risk factors were prospectively collected across all clinical trials, various dietary and lifestyle interventions that could have influenced non-HDLC and TG levels were not collected as per routine study protocol. It is difficult to perform sound statistical analyses of the comparative strength of association between non-HDLC, LDLC, and TG levels with changes in PAV, given that many of these measures are closely correlated and arise from within the same database. The restricted cubic spline curves do, however, illustrate a slightly more linear relationship between non-HDLC and changes in PAV when compared with the corresponding curves of LDLC and TG, supported by data in Figures 2-3 and the MACE data. We used simple quantifications of cholesterol levels (as opposed to direct measurements) as an attempt to offer a more clinical pragmatic approach to lipoprotein assessment. However, calculated LDLC levels as opposed to measured LDLC levels may have undermined the true biological differences observed between the presented TG data. Nuclear magnetic resonance analysis might have provided added insight, although in a large study, nuclear magnetic resonance was shown to be equivalent to that of standard lipoprotein analyses. 34 The presence of prior statin therapy might have further influenced disease progression rates and, thus, the relationships with non-HDLC and TG.
In conclusion, the present analysis is the first to describe the relationship between achieved non-HDLC and TG levels with coronary atheroma progression-regression rates in a large cohort of patients with established coronary disease. Plaque progression overall was more closely tied with changes in non-HDLC than with changes in LDLC and appeared to associate with TG levels only beyond 200 mg/dL. Importantly, lower ontreatment non-HDLC and TG levels systematically associated with plaque regression in individuals across broad categories of Model controls for differences in duration of the IVUS clinical trials. Baseline PAV, baseline and ∆ non-HDLC, and ∆ HDLC are reported per standard deviation. Other factors considered in the multivariable analysis included race (white/nonwhite), baseline BMI, history of MI, history of PCI, hypertension, smoking, baseline ACE inhibitor use, concomitant ACE use, baseline HDLC. Clinical trial was also controlled for as a random effect. ∆ indicates change; ACE, angiotensin-converting enzyme; BMI, body mass index; CI, confidence interval; HDLC, high-density lipoprotein cholesterol; IVUS, intravascular ultrasound; MI, myocardial infarction; non-HDLC, non-high-density lipoprotein cholesterol; PAV, percent atheroma volume; and PCI, percutaneous coronary intervention. Model controls for differences in duration of the IVUS clinical trials. Baseline PAV, baseline and ∆ LDLC, and ∆ HDLC are per standard deviation. Baseline and ∆ triglycerides are log-transformed. Other factors considered in the multivariable analysis included race (white/nonwhite), baseline BMI, history of MI, history of PCI, hypertension, smoking, baseline ACE inhibitor use, concomitant ACE use, baseline HDLC. Clinical trial was also controlled for as a random effect. ∆ indicates change; ACE, angiotensin-converting enzyme; BMI, body mass index; HDLC, high-density lipoprotein cholesterol; IVUS, intravascular ultrasound; LDLC, low-density lipoprotein cholesterol; MI, myocardial infarction; PAV, percent atheroma volume; and PCI, percutaneous coronary intervention.
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Non-HDL Cholesterol, Triglycerides, and Plaque Progression 2227 residual cardiovascular risk. These observations, in parallel with contemporary epidemiological and genetic data, provide a more compelling argument for non-HDLC to emerge as a primary therapeutic target for cardiovascular risk prevention, as well as providing mechanistic support for the antiatherosclerotic effects of TG-lowering strategies in patients with elevated TG levels.
